Crystal forms of saxagliptin and processes for preparing same

Details Crystal forms of saxagliptin and processes for preparing same Crystal forms of saxagliptin and processes for preparing same

2011-05-17

2011-05-17

Chung, Susannah (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S452000

Reexamination Certificate

active

07943656

ABSTRACT:
Physical crystal structures of a compound of the formula I:are provided including the free base monohydrate thereof (form H-1) and the hydrochloric acid salt thereof, including hydrochloric acid salt containing 0.75 equivalent of H2O (form H0.75-3) and hydrochloric acid salt containing 2 equivalents of H2O (form H2-1), and hydrochloric acid salt Pattern P-5, preferably in substantially pure form, and other forms as described herein, pharmaceutical compositions containing structures of compound I or IA, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures.

REFERENCES:
patent: 3674836 (1972-07-01), Creger
patent: 3983140 (1976-09-01), Endo et al.
patent: 4027009 (1977-05-01), Grier et al.
patent: 4231938 (1980-11-01), Monaghan et al.
patent: 4346227 (1982-08-01), Terahara et al.
patent: 4448784 (1984-05-01), Glamkowski et al.
patent: 4450171 (1984-05-01), Hoffman et al.
patent: 4499289 (1985-02-01), Baran et al.
patent: 4613610 (1986-09-01), Wareing
patent: 4647576 (1987-03-01), Hoefle et al.
patent: 4681893 (1987-07-01), Roth
patent: 4686237 (1987-08-01), Anderson
patent: 4759923 (1988-07-01), Buntin et al.
patent: 4871721 (1989-10-01), Biller
patent: 4924024 (1990-05-01), Biller
patent: 5006530 (1991-04-01), Angerbauer et al.
patent: 5011930 (1991-04-01), Fujikawa et al.
patent: 5177080 (1993-01-01), Angerbauer et al.
patent: 5260440 (1993-11-01), Hirai et al.
patent: 5273995 (1993-12-01), Roth
patent: 5354772 (1994-10-01), Kathawala
patent: 5385929 (1995-01-01), Bjorge et al.
patent: 5488064 (1996-01-01), Sher
patent: 5491134 (1996-02-01), Sher et al.
patent: 5506219 (1996-04-01), Robl
patent: 5541204 (1996-07-01), Sher et al.
patent: 5594016 (1997-01-01), Ueno et al.
patent: 5595872 (1997-01-01), Wetterau et al.
patent: 5612359 (1997-03-01), Murugesan
patent: 5614492 (1997-03-01), Habener
patent: 5686104 (1997-11-01), Mills et al.
patent: 5691322 (1997-11-01), Robl
patent: 5712279 (1998-01-01), Biller et al.
patent: 5739135 (1998-04-01), Biller et al.
patent: 5753675 (1998-05-01), Wattanasin
patent: 5760246 (1998-06-01), Biller et al.
patent: 5770615 (1998-06-01), Cheng et al.
patent: 5776983 (1998-07-01), Washburn et al.
patent: 5827875 (1998-10-01), Dickson et al.
patent: 5885983 (1999-03-01), Biller et al.
patent: 5962440 (1999-10-01), Sulsky
patent: 6043265 (2000-03-01), Murugesan et al.
patent: 6395767 (2002-05-01), Robl et al.
patent: 6414126 (2002-07-01), Ellsworth et al.
patent: 6515117 (2003-02-01), Ellsworth et al.
patent: 6653314 (2003-11-01), Cheng et al.
patent: 2005/0090539 (2005-04-01), Vu et al.
patent: 2005/0260712 (2005-11-01), Politino et al.
patent: 2005/0266080 (2005-12-01), Desai et al.
patent: 0 221 025 (1987-05-01), None
patent: 0 142 146 (1988-08-01), None
patent: 2 596 393 (1986-04-01), None
patent: 2 205 837 (1988-12-01), None
patent: WO 86/03488 (1986-06-01), None
patent: WO 86/07054 (1986-12-01), None
patent: WO 96/38144 (1996-12-01), None
patent: WO 97/12613 (1997-04-01), None
patent: WO 97/12615 (1997-04-01), None
patent: WO 97/21993 (1997-06-01), None
patent: WO 99/00353 (1999-01-01), None
patent: WO 99/38501 (1999-08-01), None
patent: WO 99/46272 (1999-09-01), None
patent: WO 99/61431 (1999-12-01), None
patent: WO 99/67278 (1999-12-01), None
patent: WO 99/67279 (1999-12-01), None
patent: WO 00/01389 (2000-01-01), None
patent: WO 00/38722 (2000-07-01), None
patent: WO 00/39077 (2000-07-01), None
patent: WO 01/21602 (2001-03-01), None
patent: WO 01/68603 (2001-09-01), None
patent: WO 03/033671 (2003-04-01), None
patent: WO 2006/020664 (2006-02-01), None
Morissette et al. Advanced Drug Delivery Reviews 2004, 56, 275-300.
Vippagunta et al., abstract, Vippagunta, Sudha R. “Crystalline Solids.” Advanced Drug Delivery Reviews 48(2001): 3-26.
A. Maureen Rouhi, The Right Stuff: From research and development to the clinic, getting drug crystals right is full of pitfalls, Chem. & Eng. News, 81(8), Feb. 24, 2003, 32-35.
Brittain, H.G. (Polymorphism in Pharmaceutical Solids—Drugs and the Pharmaceutical Sciences, V. 95; New York Marcel Dekker, Inc., 1999), p. 236.
Stephen M. Berge et al., Pharmaceutical Salts, Jorunal of Pharmaceutical Science, Jan. 1977, pp. 1-19, vol. 66, No. 1.
Ashworth et al., “2-Cyanopyrrolidides as Potent, Stable Inhibitros of Deipeptidyl Peptidase IV”, Biog. & Med. Chem. Lett., vol. 6, No. 10, pp. 1163-1166, (1996),.
Ashworth et al., “4-Cyanothiazolidides as Very Potent, Stable Inhibitors of Dipeptidyl Peptidase IV”, Biorg. & Med. Chem. Lett., vol. 6, No. 22, pp. 2745-2748, (1996),.
Augeri, D.J. et al., “Discovery and Preclinical Profile of Saxagliptin (BMS-477118): A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes”, J. Med. Chem., 48, pp. 5025-5037, (2005).
Biller et al., “Isoprenoid (Phosphinylmethyl)phosphonates as Inhibitor of Squalene Synthetase”, J. Med. Chem., vol. 31, No. 10, pp. 1869-1871 (1988),.
Biller et al., “Squalene Synthetase Inhibitors”, Curr. Pharm. Des, 2, pp. 1-40 (1996).
Bryn, S.R., Solid State Chem. Drugs 2nded. TOC (1999).
Capson, T.L., “Synthesis and Evaluation of Ammonium Analogs of Carbocationic Intermediates in Squalene Biosynthesis”, Dept. Med. Chem. U of Utah, Table of Contents pp. 16, 17, 40-43, 48-51, Summary, (1987),.
Corey, E. J. et al, “Application of Unreactive Analogs of Terpenoid Pyrophosphates of Studies of Multistep Biosynthesis. Demonstration That ‘Presqualene Pyrophosphate’ is Essential Intermediate on the Path to Squalene”, J. Amer. Chem. Soc. 98, pp. 1291-1293 (1976).
Cornicelli, J.A. et al., “15-Lipoxygenase and Its Inhibition: A Novel Therapeutic Target for Vascular Disease”, Current Pharmaceutical Design, vol. 5, No. 1, pp. 11-20 (1999).
Cosier, J. et al., “A Nitrogen-Gas Stream Cryostat for General X-ray Diffraction Studies”, J. Appl. Cryst., vol. 19, pp. 105-107 (1986).
Ghiselli, G., “The pharmacological profile of FCE 27677: a novel ACAT inhibitor with potent hypolipdemic activity mediated by selective suppression of the hepatic secretion of ApoB100-containing lipoprotein”, Cardiovasc. Drug Rev. 16(1):16-30(1998).
Hara, S., “Ileal Na+/bile acid Contransporter Inhibitors”, Drugs of the Future, 24(4), pp. 425-530 (1999).
Hughes, T.E. et al., “(1-[[[2-[(5-Cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2- cyano-(S)-pyrrolidine), a Slow-Binding Inhibitor of Dipeptidyl Peptidase IV”, Biochem. 38, pp. 11597-11603 (1999).
Johannsson, G. et al., “Growth Hormone Treatment of Abdominally Obese Men Reduces Abdominal Fat Mass, Improves Glucose and Lipoprotein Metabolism, and Reduces Diastolic Blood Pressure”, Journal of Clinical Endocrinology and Metabolism, vol. 82, No. 3, pp. 727-734 (1997).
Krause, B.R. et al. “ACAT Inhibitors: Physiologic Mechanisms for Hypolipidemic and Anti-Atherosclerotic Activities in Experimental Animals”, Inflammation: Mediators and Pathways, CRC Press Inc, publ., Ruffolo, Jr., R.R. et al., eds., pp. 173-198 (1995).
McClard, R.W. et al., “Novel Phosphonylphosphinyl (P-C-P-C) Analogues of Biochemically Interesting Diphosphates. Syntheses and Properties of P-C-P-C Analogues of Isopentenyl Diphosphate and Dimethylallyl Diphosphate”, J. Am. Chem. Soc. 109, pp. 5544-5545 (1987).
Mullin, J.W., “Programmed Cooling of Batch Crystallizers”, Chem. Eng. Sci, vol. 26, pp. 369-377 (1971).
Morrison, J.F. et al., “The Behavior and Significance of Slow-Binding Enzyme Inhibitors”, Advances in Enzymology and Related Areas of Molecular Biology, vol. 61, John Wiley & Sons, Inc., publ., Meister, A., ed., pp. 201-206 (1988).
Murakami, K. et al., “A Novel Insulin Sensitizer Acts as a Coligand for Peroxisome Proliferator-Activated Receptor-α(PPAR-α) and PPAR-γ”, Diabetes vol. 47, pp. 1841-1847 (1998).
Nicolosi, R.J. et al., 

Affiliated with

Also associated with

Rating

Crystal forms of saxagliptin and processes for preparing same does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Crystal forms of saxagliptin and processes for preparing same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystal forms of saxagliptin and processes for preparing same will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2639807